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Fibroblast growth factor (FGF) signaling has been shown to regulate lung epithelial development but its influence on mesenchymal
differentiation has been poorly investigated. To study the role of mesenchymal FGF signaling in the differentiation of the mesenchyme and its
impact on epithelial morphogenesis, we took advantage of Fgfr2c+/Δ mice, which due to a splicing switch express Fgfr2b in mesenchymal tissues
and manifest Apert syndrome-like phenotypes. Using a set of in vivo and in vitro studies, we show that an autocrine FGF10–FGFR2b signaling
loop is established in the mutant lung mesenchyme, which has several consequences. It prevents the entry of the smooth muscle progenitors into
the smooth muscle cell (SMC) lineage and results in reduced fibronectin and elastin deposition. Levels of Fgf10 expression are raised within the
mutant mesenchyme itself. Epithelial branching as well as epithelial levels of FGF and canonical Wnt signaling is dramatically reduced. These
defects result in arrested development of terminal airways and an “emphysema like” phenotype in postnatal lungs. Our work unravels part of the
complex interactions that govern normal lung development and may be pertinent to understanding the basis of respiratory defects in Apert
syndrome.
© 2006 Elsevier Inc. All rights reserved.Keywords: FGF10; FGFR2b; Smooth muscle cells; Lung; Apert syndromeIntroduction
Lung development is orchestrated by cross-talk between
epithelial and mesenchymal cells. The epithelium and mesench-
yme generate diverse cell types and this process is tightly
coordinated with branching morphogenesis.
Very little is known about the origin and signals that regulate
the differentiation of mesenchymal cell derivatives. We have
previously reported that progenitors for parabronchial SMC lie
at the most distal tips of each branch (Mailleux et al., 2005;
Warburton et al., 2000). Soon after exiting this distal domain, a
differentiation program is initiated likely in response to a tightly⁎ Corresponding authors.
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doi:10.1016/j.ydbio.2006.07.001regulated combination of activating and inhibitory signals
(Hogan, 1999). Increasing evidence suggests that the balance
between these signals is critical to control the differentiation of
the SMC progenitors.
Families of 22 FGFs and four FGF receptors (FGFRs 1–4)
have been identified in mammals. Typically, FGFRs are
comprised of an extracellular region composed of two or
three immunoglobulin-like (Ig) domains, a transmembrane
segment and an intracellular tyrosine kinase domain (Johnson
and Williams, 1993; McKeehan et al., 1998). Alternative splic-
ing of the exons that encode the carboxy terminal half of the
third Ig domain in Fgfrs-1, -2 and -3 results in receptor iso-
forms termed ‘IIIb’ or ‘IIIc’, each with respectively distinct
ligand-binding specificity and tissue distributions (Ornitz et al.,
1996). The Fgfr2 gene splice variant containing the IIIb exon
(Fgfr2b) is expressed mainly in epithelial cells and is activated
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nantly within the mesenchyme. By contrast, FGFR2-IIIc
(FGFR2c) is expressed primarily in the mesenchyme and
apart from FGF1, is activated by a different set of FGF ligands,
namely, FGFs-2, -4, -6, -8, -9 and -18 (Bellusci et al., 1997;
Mason, 1994; Ornitz et al., 1996; Orr-Urtreger et al., 1993;
Peters et al., 1992; Yamasaki et al., 1996). FGF9 is known to be
a key regulator of distal lung development. It is expressed
initially in the mesothelium and epithelium but later becomes
restricted to the mesothelium (Colvin et al., 1999). Sandwiched
between these two cell layers is the lung mesenchyme and
FGF9 is thought to act on the mesenchyme via FGFR2c (Ornitz
et al., 1996). Inactivation of Fgf9 results in reduced mesench-
ymal cell proliferation and consequently reduced secondary
branching of the lung epithelium (Colvin et al., 2001). Treat-
ment of embryonic lung mesenchymal explants with FGF9
inhibits SHH-induced differentiation of the mesenchyme into
SMCs but does not affect mesenchymal cell proliferation
(Weaver et al., 2003). Therefore, mesenchymal FGF signaling is
seemingly crucial for maintaining lung mesenchymal progeni-
tor cells in an undifferentiated state.
To further analyze the function of mesenchymal FGFR2
signaling in the differentiation of the lung mesenchymal
progenitor cells and its impact on lung epithelial cells, we
have studied the consequences of a gain-of-FGFR2 function
mutation arising from the ectopic expression of Fgfr2b within
the lung mesenchyme, alongside Fgfr2c. This genetic aberra-
tion takes places when one copy of Fgfr2 exon 9 (IIIc exon) is
deleted as in Fgfr2c+/IIIcΔ mice (called Fgfr2c+IΔ for simplifica-
tion). This interferes with the normal balance of exon IIIb/IIIc
alternative splicing (Hajihosseini et al., 2001), seemingly
perturbing the tight molecular constraints placed on tissue-
specific expression of IIIb and IIIc isoforms (Wagner et al.,
2005). Co-expression of Fgfr2b and Fgfr2c in the lung
mesenchyme would render these cells responsive to a broader
range of FGF ligands, in particular FGF10, which is produced
by mesenchymal cells themselves. Because the two receptor
isoforms are otherwise identical in their intracellular sequence,
mesenchymal cells perceive this as a net gain-of-FGFR2
function.
Using this in vivo approach, we determined how this gain-of-
FGFR2 activity impinges on the cellular and molecular mecha-
nisms underlying lung development and the interaction between
mesothelial, mesenchymal and epithelial cells. Chief among
these is the finding that increased mesenchymal signaling inhi-
bits a progression of mesenchymal differentiation to the smooth
muscle cell lineage.
Results
Fgfr2c+/Δ mice suffer from a complex lung phenotype
E11.5 wild-type (WT) mouse lungs exhibit four primitive
lobes on the right (cranial, medial, caudal and accessory) and
one lobe on the left. At E11.5, Fgfr2c+/Δ lungs also have four
lobes, but one of these, the accessory lobe, consists solely of
mesenchyme and eventually regresses by E12.5 (data notshown). At E12.5, epithelial branching is reduced as judged by
the presence of fewer peripheral epithelial buds (4.6±0.5 versus
7.6±0.5 in WT, n=5, P<0.05; data not shown). By E14.5,
Fgfr2c+/Δ lungs continue to show a severe impairment in
epithelial branching and absence of the accessory lobe (arrow-
heads in Figs. 1a–a′) and the remaining three right lobes are
fused (Figs. 1a, a′). Moreover, Fgfr2c+/Δ lungs show a more
abundant mesenchyme (arrow in Fig. 1b′), as well as dilated
distal airways (insets in Fig. 1b, b′). At Postnatal day 0 (P0)
(data not shown) and P3, WT and Fgfr2c+/Δ lungs are
similar in size (Figs. 1c, c′), but mutant lungs show an
“emphysema-like” arrested development of the terminal
airways (Fig. 1d, arrow in d′) characterized by defects in
the formation of secondary septa and thinner alveolar walls
(insets in Figs. 1d, d′). Fgfr2c+/Δ mice die by P7 because of
growth retardation, bone and visceral defects (Hajihosseini et
al., 2001) thus precluding analysis at later postnatal stages.
Phospho-histone H3 staining at E12.5, E13.5 and E14.5 WT
and mutant lungs reveals that the observed branching defects
involve perturbed rates of cell proliferation. Mutant E12.5 and
E13.5 lungs contain significantly fewer mitotic epithelial cells
compared to wild type (E12.5: 7.9±2% versus 20±2%, n=3,
P≤0.05; data not shown; E13.5: 13.5±3.0% versus 22.8±
0.8%, n=3, P≤0.05; data not shown), but no significant dif-
ference is seen in the proliferation of mesenchymal cells (E12.5:
16.3±2.% versus 16.5±1.5%, n=3, P=0.5; data not shown;
E13.5: 14.8±3.8% versus 12.5±2.0%, n=3, P=0.2; data not
shown). Hence, at E12.5 and E13.5, the more abundant
mesenchyme likely reflects an imbalance in the epithelial to
mesenchymal cell ratio resulting from reduced epithelial
proliferation, rather than from mesenchymal hyperproliferation.
However, at E14.5 when FGF10 expression has reached higher
levels (Bellusci et al., 1997), increased mesenchymal proli-
feration is observed in the mutant lungs compared to wild type
(18.7±1.2% versus 10.1±1.0%, n=3, P≤0.05), while there are
fewer mitotic epithelial cells compared to wild type (11.6±1.8%
versus 22.4±2.3%, n=3, P≤0.05) (Fig. 1e). In addition, at
14.5, the Fgfr2c+/Δ mesenchyme shows an increase in the
number of phospho-ERK (P-ERK)-positive cells compared to
the wild-type mesenchyme (2.3±0.2% versus 1.1±0.2%, n=3,
P≤0.05), while there are less P-ERK-positive epithelial cells in
Fgfr2c+/Δ versus wild-type lungs (2.3±0.4% versus 3.7±0.3%,
n=3, P≤0.05) (Figs. 1f, g and g′). Elevated mesenchymal
FGF signaling in Fgfr2c+/Δ mice therefore correlates with an
increase in P-ERK-positive cells in the mesenchyme of mutant
versus WT lungs.
Ectopic activation of FGFR2b signaling within Fgfr2c+/Δ
mesenchyme
Ectopically expressed Fgfr2b within the lung mesenchyme
would render this tissue mostly responsive to FGF10, the major
FGFR2b ligand during the pseudoglandular stage that is
produced by mesenchymal cells themselves and which
normally acts solely on the epithelium. To demonstrate ectopic
expression of FGFR2b in the mesenchyme, we first compared
the ability of mesenchymal cells isolated from E14.5 WT and
Fig. 1. Abnormal lung development in Fgfr2c+/Δ embryos and neonates. Appearance of WT and Fgfr2c+/Δ lungs at E14.5 (a, a′) and P3 (b, b′) with corresponding
higher magnifications of the left lobe shown below each panel (c–d′); WT (c, d) and Fgfr2c+/Δ (c′, d′). Insets in panels (c–d′), H&E stained sections through the lungs.
(e, f) Percentage of mitotic (e) and P-ERK (f)-positive cells in the mesenchyme and epithelium of E14.5 WT and Fgfr2c+/Δ lungs. (g, g′) Representative P-ERK
staining of E14.5 WT and Fgfr2c+/Δ lung sections. Cranial (cr), medial (me), caudal (ca) and accessory lobe (ac).
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and to FGF10, which can act via FGFR2b and FGFR1b (Ornitz
et al., 1996). We used levels of ERK phosphorylation as a
readout for FGFR signaling (Schlessinger, 2004). FGF2, a
ligand for FGFR2c, was used as a positive control for the ERK
phosphorylation assay and as expected could elicit a response in
both genotypes. By contrast, only mutant mesenchymal cells
responded to FGFs 7 and 10, indicative of the presence of their
receptors only in mutant mesenchyme (Figs. 2a, a′). Since
FGF10 is the only FGFR2b ligand expressed during the first
phase of the pseudoglandular stage (E9.75–E13.5) (Bellusci et
al., 1997), these observations strongly suggest that autocrine
FGF10/FGFR2b signaling underlies the net gain-of-FGFR2
function in Fgfr2c+/Δ mesenchyme, as this tissue becomes
responsive to both FGFR2b and FGFR2c-activating ligands.
In a set of studies described below, we then investigated how
this gain-of-FGFR2 activity impinges on the cellular andmolecular mechanisms underlying lung development and the
interaction between mesothelial, mesenchymal and epithelial
cells.
Impaired SMC differentiation in Fgfr2c+/Δ lungs
In vitro, lung mesenchymal cells differentiate into SMCs and
express α-smooth muscle actin (α-SMA) within 24 h of culture
(Yang et al., 1998). Treatment with FGF10 impairs this ability in
mutant but not WT mesenchymal cells (Figs. 2b, b′), suggesting
that gain-of-FGFR2 signaling within the mutant mesenchyme
inhibits the entry of the undifferentiated mesenchymal cells into
the SMC lineage. We then tested whether this holds for alveolar
SMC in vivo. Staining of Fgfr2c+/Δ lungs for α-SMA in the
distal respiratory airway, where the alveoli will form, revealed a
general reduction in the expression of this SMC marker from
E17.5 onwards (data not shown). This decrease was more
Fig. 2. Perturbed mesenchymal FGFR2 signaling level and expression of α-smooth muscle actin and Elastin. (a, a′) Western blot from isolated primary culture of WT
(a) and Fgfr2c+/Δ (a′) lung mesenchyme stimulated for 5 min with FGF2 (250 ng/ml), FGF7 (100 ng/ml) or FGF10 (500 ng/ml). (b, b′) IF staining for α-SMA on
isolated primary mesenchymal cells cultured in vitro for 24 h in the presence of 500 ng/ml FGF10. (c, c′) IF for α-SMA in P3 WT and Fgfr2c+/Δ lungs. SMC around
the blood vessels (bv) did not show any changes in α-SMA expression. (d, d′) IF staining for Elastin in P3WTand Fgfr2c+/Δ lungs reveals a drastic decrease in Elastin
expression in the mutant (d′).
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elastin deposition (Figs. 2d, d′).
Presence of an autocrine FGF10/FGFR2b feedback loop in
Fgfr2c+/Δ mesenchyme
Fgf9−/− lungs show reduced mesenchymal Fgf10 expres-
sion (Colvin et al., 2001). Since FGFR2b and FGFR2c have
identical cytoplasmic domains, autocrine FGF10-FGFR2b
signaling in the mutant mesenchyme may be falsely perceived
by this tissue as increased FGF9-FGFR2c signaling. To
investigate whether in the developing lung the level of
Fgf10 expression in the mesenchyme is regulated by levels of
FGFR2 signaling, we examined by whole mount in situ
hybridization (WMISH) whether the gain-of-FGFR2 activity
raises the level of Fgf10 expression. We found that Fgf10
expression is upregulated in Fgfr2c+/Δ lungs, when compared
to WT (Figs. 3a–b′). Vibratome sectioning confirmed the
increase in Fgf10 expression in the peripheral mesenchyme
(insets in Figs. 3b and b′). We found that Tbx5, an upstream
regulator of Fgf10 expression (Cebra-Thomas et al., 2003;
Sakiyama et al., 2003) and Spry4, an inducible antagonist of
FGFR signaling (de Maximy et al., 1999; Furthauer et al.,
2002), are also upregulated in the mesenchyme of the mutant
lungs (Figs. 3c–f′). Expression of transcription factor Foxf1
was markedly decreased in mutant lungs (Figs. 3g–h′) and
interestingly Foxf1+/− mice carry a lung phenotype similar to
Fgfr2c+/Δ mice, i.e., fusion of the right lobes and a missing
accessory lobe (Lim et al., 2002; Mahlapuu et al., 2001).
We then performed real-time RT-PCR to confirm the results
obtained by WMISH. To avoid any complications arising fromdifferences in the ratio of epithelium versus mesenchyme in
whole Fgfr2c+/Δ lungs, we tested the effect of recombinant
FGF7, a specific FGFR2b activating ligand, on primary
cultures of lung mesenchymal cells isolated from E14.5
mutant and wild-type lungs. Wild-type mesenchymal cells do
not express Fgfr2b (data not shown) and accordingly do not
respond to FGF7 (Fig. 2a). By contrast, Fgfr2c+/Δ mesenchy-
mal cells, which express Fgfr2b, showed marked changes in
gene expression in response to FGF7, namely, elevated Fgf10
(600%±200%, n=4, P≤0.05), Tbx5 (200%±13%, n=3,
P≤0.05), and Spry4 (500%±147%, n=3, P≤0.05) expres-
sion, but reduced Foxf1 expression (40%±10%, n=3,
P≤0.05). No significant changes in mesenchymal gene
expression, including Fgf10, were observed in untreated
mutant versus wild-type mesenchyme, suggesting that in
vitro, endogenous FGF10 in Fgfr2c+/Δ mesenchymal cells is
not capable of inducing sufficient autocrine signaling, as it gets
diluted into the medium. A similar observation has been made
with Fgfr2c+/Δ lungs grown in vitro (Fig. 6). Overall these
results give strong support for the upregulation of Fgf10
expression on a per cell basis through a FGF10/FGFR2b
autocrine feedback loop maintaining high levels of Fgf10
expression, likely via Tbx5 upregulation.
Epithelial FGF signaling is not increased in Fgfr2c+/Δ lungs
The increase in Fgf10 expression in the mesenchyme of
Fgfr2c+/Δ lungs lead us to investigate whether this would
translate into increased FGF signaling in the epithelium. We
examined the expression of Bmp4 and Sprouty2 (Spry2), two
known targets of FGF10 signaling in lung epithelium. Fig. 4
Fig. 3. Quantitative changes in the expression of Fgf10 and several signalingmodulators inFgfr2c+/Δ lungs. Comparison of gene expression levels in E13.5 lungs inWT
(a–h) andmutant (a′–h′) lungs (n=3 for each probe) byWMISH. (a–b′) Fgf10 expression. (b and b′) Comparison of magnified views and the corresponding vibratome-
generated sections (insets in each panel) reveals an increase in Fgf10 expression. Mutant lungs also show an increase in Tbx5 (d versus d′) and Spry4 (f versus f′), but
reduced levels of Foxf1 (h versus h′) expression.
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similar to that of WT (Figs. 4a–b′). However, Fgf10 is not the
sole regulator of Bmp4 expression (Mailleux et al., 2001). The
expression of Spry2, which is a more sensitive indicator of
epithelial FGF signaling than Bmp4 expression (Mailleux et
al., 2001), was slightly down regulated in Fgfr2c+/Δ lungs
when compared to WT (Figs. 4c–d′, arrows in f, f′),
suggesting that there is a modest decrease in epithelial FGF
signaling in Fgfr2c+/Δ lungs. Corresponding vibratome
sections (Figs. 4e–f′) additionally revealed an expansion of
the Sprouty2 negative domain located between the two
prospective buds in Fgfr2c+/Δ lungs (double arrow in Figs.
4f, f′). This decrease in Sprouty2 expression correlates with
the decrease in proliferation and P-ERK-positive cells in the
mutant epithelium (Figs. 1e and f). We propose that decreasedepithelial FGF signaling is likely the result of FGF10 being
retained and/or consumed by the mesenchyme and therefore
not being available to act on the epithelium. A recent report
has shown that expression of β-catenin, a main effector of
canonical Wnt signaling, was a target of FGF10 signaling (Lu
et al., 2005). In the next set of studies, we compared the status
of the Wnt signaling in the wild-type and mutant lungs.
Canonical Wnt signaling is decreased in Fgfr2c+/Δ lungs
Canonical Wnt signaling regulates lung branching morpho-
genesis (Mucenski et al., 2003; Okubo and Hogan, 2004) and
general inhibition of Wnt signaling by treatment with DKK1
results in dilated distal airways (De Langhe et al., 2005). We
found that decreased branching and dilated distal airways in
Fig. 4. Epithelial FGF signaling is not increased in Fgfr2c+/Δ lungs. WMISH in E13.5 WT and mutant lungs. (a–b′) Bmp4 and (c–d′) Spry2 expression. (e–f′)
Vibratome sections of the Spry2 lungs.
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expression in the epithelium (Figs. 5a–b′). In a more direct
approach, we measured the level of β-galactosidase activity in
Fgfr2c+/Δ/TOPGAL+/− mice and could detect a reduction in the
levels of canonical Wnt signaling in distal epithelium
(DasGupta and Fuchs, 1999) (Figs. 5c–d′). Supporting this
result, Figs. 5e′–f′ show a reduction in nuclear β-catenin
protein localization in the epithelium of E13.5 Fgfr2c+/Δ lungs
compared to the corresponding wild-type control lungs (Figs.
5e–f). We previously reported that inhibition of Wnt signaling
in the lung leads to a reduction in Fibronectin (FN) deposition,
which is associated with decreased branching and dilation of the
distal airways (De Langhe et al., 2005). The level of FN
deposition is also significantly decreased in the distal region of
Fgfr2c+/Δ lungs (arrowheads in Figs. 5g–h′), as a likely result
of decreased Wnt signaling.
Growing the Fgfr2c+/Δ lungs in vitro alleviates the
mesenchymal differentiation defects
Earlier results suggested that in response to culturing, the
endogenous FGF10 produced by Fgfr2c+/Δ mesenchymal may
become diluted into the medium and would be insufficient toinduce an autocrine signaling loop. To examine this possibility
further, we analyzed FN deposition and α-SMA expression in
wild-type and Fgfr2c+/Δ lung explants grown for 72 h in vitro in
the presence or absence of FGF10. FGF10 treatment does not
affect SMC differentiation and FN deposition in WT lungs
(compare Figs. 6b to a). By contrast, in the presence of
exogenous FGF10, Fgfr2c+/Δ lungs show decreased FN
deposition and α-SMA expression and a more abundant
mesenchyme (arrows in Fig. 6b′; compare Fig. 6b′ to a and b)
comparable to what we observed in whole lungs in vivo.
Remarkably, without exogenous FGF10, cultured Fgfr2c+/Δ
lungs showed a normal FN deposition and α-SMA expression
profile (compare Figs. 6a′ to a).
We also obtained experimental support that there are no
inherent defects in the response of the mutant epithelium to
FGF10. Embryonic lung endoderm isolated from Fgfr2c+/Δ;
TOPGAL+/− and Fgfr2c+/+;TOPGAL+/− mice respond equally
well to exogenous FGF10 by branching (compare Figs. 6e–f′).
Moreover, in the absence of mesenchyme, level of TOPGAL
activity in the epithelium was restored to normal in Fgfr2c+/Δ
lungs (compare inset in Figs. 6f, f′). We therefore propose that
the in vitro “rescue” of the mutant lungs is due to decreased
FGF10 signaling in the mesenchyme. Our results also confirm
Fig. 5. Decreased Wnt signaling and fibronectin deposition in Fgfr2c+/Δ lungs. (a–f) Assessment of Wnt signaling levels by WMISH or TOPGAL staining of E13.5
WT and mutant lungs. (b, b′) Increased expression of Wnt-signaling antagonist in Fgfr2c+/Δ lungs compared to WT (a, b). (c–d′) LacZ staining as a read out of
TOPGAL activity in E13.5 Fgfr2c+/+/TOPGAL+/− and Fgfr2c+/Δ/TOPGAL+/− lungs. Notice the decrease in canonical Wnt signaling in the Fgfr2c+/Δ lungs. (e–f′)
IHC for β-catenin showing decreased nuclear β-catenin in the epithelium of the mutant lung (e′, f′, arrows) compared to the wild-type (e, f, arrows). (g–h′) IF staining
for FN showing reduced FN deposition in the Fgfr2c+/Δ lungs (arrow heads).
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is not sufficiently capable of activating FGFR2b expressed
in Fgfr2c+/Δ mesenchyme.
A heterozygous knockdown of Fgf10 levels partially rescues the
lung phenotype of Fgfr2c+/Δ lungs
Results obtained so far suggest that excessive mesenchymal
FGF10/FGFR2b signaling is the underlying cause of the defects
observed in Fgfr2c+/Δ lungs. To test whether decreasing Fgf10gene dosage in vivo would decrease the severity of the lung
phenotype in Fgfr2c+/Δ mice, we crossed CMV-Cre; Fgf10+/−
mice with Fgfr2cflox/flox mice to generate Fgfr2c+/Δ; Fgf10+/−
mice. Similar to the P3 lungs (Fig. 1f′), P0 Fgfr2c+/Δ lungs
(n=3) display a defect in the formation of secondary septa (Fig.
7b) compared to WT lungs (Fig. 7a). Fgfr2c+/Δ; Fgf10+/− lungs
(n=3) show a partial rescue of this process with thicker alveolar
walls and more secondary septa compared to Fgfr2c+/Δ lungs
(compare Figs. 7c and b). These changes in peripheral pul-
monary alveolar size were quantified by morphometric
Fig. 6. In vitro rescue of Fgfr2c+/Δ mesenchymal differentiation defects. (a–b′) Explants of E11.5 of WT (a, b) and Fgfr2c+/Δ (a′, b′) lungs grown for 72 h in the
absence (a, a′) and presence (b, b′) of FGF10, stained for α-SMA and FN. (c–d′) Appearance of Fgfr2c+/+/TOPGAL+/− (c, d) and Fgfr2c+/Δ/TOPGAL+/− (c′, d′) lung
endoderm after t=0 h (c, c′) and t=72 h (d, d′) of culture in Matrigel™ in the presence or absence of FGF10.
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shows a rescue in the size of the alveoli (* in Figs. 7a–c) of
Fgfr2c+/Δ; Fgf10+/− lungs compared to Fgfr2c+/Δ lungs (67±5Fig. 7. Genetic knockdown of Fgf10 levels partially rescues the Fgfr2c+/Δ lung pheno
WT (a), Fgfr2c+/Δ (b), and Fgfr2c+/Δ;Fgf10+/− (c) P0 lungs. Note the similarity of p
lungs. (d) Morphometric measurement of mean linear intercept in each genotype. (e–
lungs. (h, i) Percentage of mitotic (h) and P-ERK (i)-positive cells detected in the m
Fgfr2c+/Δ abbreviated to ‘2c’ and Fgfr2c+/Δ;Fgf10+/−, to ‘Res’.μm versus 106±16 μm, P<0.05). Additional evidence of the
rescue was provided by the detection of alveolar SMCs in the
Fgfr2c+/Δ; Fgf10+/− lungs (inset in Fig. 7c).type. (a–c) Comparison of branching patterns in hematoxylin-stained sections of
anels (a) and (c). Inset in panel (c), α-SMA expression in Fgfr2c+/Δ; Fgf10+/−
g) WMISH for Spry2 in E14.5 WT (e), Fgfr2c+/Δ (f), and Fgfr2c+/Δ;Fgf10+/− (g)
esenchyme and epithelium of E14.5 Fgfr2c+/Δ, and Fgfr2c+/Δ;Fgf10+/− lungs.
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can be rescued by decreasing FGF10 dosage. However, when
reducing levels of Fgf10 expression in vivo at an early
developmental stage (E14.5), we found that mesenchymal pro-
liferation is reduced compared to the Fgfr2c+/Δ lungs [11.3±
1.7% (Fgfr2c+/Δ; Fgf10+/−) versus 18.7±1.2% (Fgfr2c+/Δ),
n=3, P≤0.05] while the decrease in epithelial proliferation
persists in the Fgfr2c+/Δ; Fgf10+/− lungs (11.3±1.5%
(Fgfr2c+/Δ; Fgf10+/−) versus 11.6±1.8% (Fgfr2c+/Δ), n=3,
P=0.4) (Fig. 7h). P-ERK immunostaining indicates a small but
significant decrease in the number of P-ERK-positive cells in
the mesenchyme of Fgfr2c+/Δ; Fgf10+/−versus Fgfr2c+/Δ
lungs (1.9±0.2% (Fgfr2c+/Δ; Fgf10+/−) versus 2.3±0.2%
(Fgfr2c+/Δ), n=3, P≤0.05), suggesting that there is a reduc-
tion in mesenchymal FGF signaling in the Fgfr2c+/Δ; Fgf10+/−
compared to Fgfr2c+/Δ lungs. We propose that this decrease
allows for the proper differentiation of the mesenchyme (the
so-called “rescue”). Indicative of a further reduction in epithe-
lial FGF signaling in the Fgfr2c+/Δ; Fgf10+/− versus Fgfr2c+/Δ
lungs, we observe a further decrease in Spry2 expression (Figs.
7e–g) and a further reduction in the number of P-ERK-positive
cells in the epithelium (1.8±0.2% (Fgfr2c+/Δ; Fgf10+/−) versus
2.3±0.4% (Fgfr2c+/Δ), n=3, P≤0.05) (Fig. 7i).
Discussion
An autocrine FGF10/FGFR2b signaling loop in Fgfr2c+/Δ
lung mesenchyme perturbs the interdependence between the
epithelium, mesenchyme and mesothelium
During the early pseudoglandular phase of lung development
(E9.5–E14), FGF9 is secreted by both the epithelium and
mesothelium, and is the major FGF ligand acting on the
mesenchyme via FGFR1c/FGFR2c (Bellusci et al., 1997;
Colvin et al., 1999). Lungs null for Fgf9 show agenesis of the
distal mesenchyme (Colvin et al., 2001) suggesting that FGF9
acts as a survival factor for the mesenchyme. In our model, the
establishment of an autocrine FGF10/FGFR2b signaling loop in
the mesenchyme results in overactivation of the FGF signaling
pathway in the distal mesenchyme and appears to abolish the
need for FGF9. This mouse model is indeed very useful to study
the role of mesenchymal FGF signaling in the lung. Over-
expression of Fgf9 in the distal embryonic lung epithelium in
vivo has been published recently (White et al., 2006). However,
in the embryonic lung, we have previously shown that FGF9 is
capable of acting both on the epithelium and the mesenchyme
(Del Moral et al., 2006). Therefore, the results obtained by
overexpressing Fgf9 in the embryonic lung will not be the
consequence of activating FGF signaling only in the mesen-
chyme. The Fgfr2c+/Δ mutant mice therefore represent a unique
opportunity to understand the role of mesenchymal FGF
signaling in the lung in vivo.
Fgf10 is a downstream target of mesenchymal FGF signaling
Our results indicate that increased FGF10-mediated
mesenchymal FGF signaling in Fgfr2c+/Δ lungs leads to in-creased Fgf10 expression (Fig. 3). In agreement with this result,
we recently showed that FGF9, which is the physiological
FGF ligand acting on the lung mesenchyme during the
pseudoglandular phase, is capable of promoting Fgf10 expres-
sion in primary culture of embryonic lung mesenchyme (Del
Moral et al., 2006). In addition, recent work by White et al.
(2006) also shows that mesenchymal FGF10 expression levels
can be increased when Fgf9 is overexpressed under the
control of the surfactant protein C promoter. Together these
observations demonstrate that FGF9 maintains the prolifera-
tion and promotes Fgf10 expression in the submesothelial
mesenchyme.
Parallel FGFR signaling loops in lung and limb development
Strong parallels can then be drawn between interactions that
govern limb and lung development. In the early limb bud, FGF8
expressed in the AER (Agarwal et al., 2003; Galceran et al.,
1999) signals to the mesenchyme to maintain Tbx5 expression,
which in turn controls Fgf10 expression (Agarwal et al., 2003;
Sekine et al., 1999; Takeuchi et al., 2003). A similar pathway
appears to exist in the lung. FGF9 expressed in the mesothelium
acts on the adjacent distal mesenchyme to regulate Fgf10
expression. Our results suggest that Tbx5, which regulates
Fgf10 expression in the lung mesenchyme (Cebra-Thomas et al.,
2003; Sakiyama et al., 2003), is itself regulated by FGF
signaling, just as it is in the limb (Agarwal et al., 2003; Takeuchi
et al., 2003).
Increased mesenchymal FGF signaling in Fgfr2c+/Δ lungs
indirectly inhibits epithelial branching
Our analysis of the defects in Fgfr2c+/Δ lungs points to two
mechanisms of action. First, the increase in mesenchymal FGF
signaling in response to FGF10 prevents the proper differentia-
tion of the mutant mesenchyme. Second, the reduction in
epithelial FGF10 signaling results in decreased proliferation,
ERK phosphorylation and Spry2 expression in the epithelium.
These epithelial defects are associated with lower levels of
canonical Wnt signaling activation, supporting the previous
observation that FGF10 could directly control Wnt signaling
activation in the epithelium at least during the first phase of the
pseudoglandular stage (Lu et al., 2005). In harmony with these
results, the analysis of Fgf10 hypomorphic lungs (Mailleux et
al., 2005) also shows a strong reduction in canonical Wnt
signaling activation (Bellusci, unpublished observation).
The potential involvement of FGF10 in Apert-like lung
pathology
Fgfr2c+/Δ mice model a congenital human syndrome, Apert
syndrome, which arises through gain-of-FGR2 activity and
encompasses a host of skeletal and visceral defects (Cohen and
Kreiborg, 1993). The visceral defects include cardiovascular,
genitourinary, respiratory and gastrointestinal anomalies (Cohen
and Kreiborg, 1993). The Fgfr2 splicing defect exhibited in
Fgfr2c+/Δ mice is representative of a rare Apert-causing FGFR2
61S.P. De Langhe et al. / Developmental Biology 299 (2006) 52–62mutation (Oldridge et al., 1999) but the range and severity of
phenotypes in Fgfr2c+/Δ mice are remarkably reminiscent of
mice that carry a more commonApert mutation (FGFR2+/S252W)
(Wang et al., 2005) as well as of the patients themselves. Lung
defects in Apert syndrome patients similar to those reported here
have been described (Cohen and Kreiborg, 1992; Cohen and
Kreiborg, 1993). These include fusion of tracheal cartilage rings,
absent accessory lobe and defective interlobular septation. Using
this mutant mouse, we also show a peripheral lung phenotype
arising from defective mesenchymal differentiation. This
peripheral lung phenotype has not been previously described
in patients with Apert syndrome. However, such intricate
peripheral lung defects may have been overlooked or not
analyzed in human patients. Our study shows that the Fgfr2c+/Δ
lung phenotype is primarily, the consequence of a mesenchymal
defect. A contributing factor in this mesenchymal pathology is
the increased level of Fgf10 expression as indicated by our
finding that a genetic knockdown of Fgf10 can partially rescue
the newly reported peripheral lung phenotype.
Our results indicate that the establishment of an FGF10/
FGFR2b autocrine feedback loop in the mesenchyme is the
primary cause of lung defects in Fgfr2c+/Δ mice. The multiple
downstream effects that we have characterized should help in
understanding the basis and alleviation of lung pathology in
Apert syndrome.Materials and methods
Transgenic embryos
Fgfr2c+/Δ mice were generated as previously described (Hajihosseini et al.,
2001) and maintained in an outbred background, all in accordance to
institutional transgenic breeding regulations. Male mice containing the targeted
floxed allele were crossed with homozygous CMV-Cre transgenic female mice
expressing Cre recombinase in the germ cells (Jackson Laboratories). TOPGAL
and Fgf10LacZ/+ mice were generously provided by Drs. E. Fuchs and R. Kelly.
β-Galactosidase staining
β-Galactosidase staining of E13.5 lungs from Fgfr2c+/Δ embryos containing
the TOPGAL or Fgf10LacZ alleles was performed as previously described (De
Langhe et al., 2005).
In situ hybridization
Whole-mount in situ hybridization was performed on E13.5 embryonic
lungs as previously described (Winnier et al., 1995). The following mouse
cDNAs were used to generate antisense riboprobes: 1.5 kb Bmp4 (Winnier et al.,
1995), 818 bp Dkk1 (Dr. Niehrs), 584 bp Fgf10 (Bellusci et al., 1997), 1.1 kb
Spry4 (de Maximy et al., 1999), 948 bp Spry2 (Mailleux et al., 2001), and 1.1
kb Tbx5 (Dr. Papaioannou).
Isolation of mesenchymal cells
Mesenchymal cells from E13.5 or E14.5 WT and Fgfr2c+/Δ lungs were
isolated according to (Lebeche et al., 1999).
Organ culture and measurement of peripheral lung buds
Lung explants were cultured as previously described (De Langhe et al.,
2005) in the presence or absence of 500 ng/ml FGF10 (R&D systems).In vitro assay of isolated lung epithelium
Lungs epithelium was isolated and cultured as previously described
(Bellusci et al., 1997) in presence of 500 ng/ml FGF10 (R&D systems).
Immunohistochemistry
Immunohistochemistry for β-catenin was performed on paraffin sections of
formalin fixed lungs. IHC was performed with the Envision kit from Dako
cytomation, β-catenin Ab (BD biosciences) was used at 1:100. Mesenchymal
cells and lung sections were treated with the following antibodies as described in
De Langhe et al. (2005): Cy3 conjugated-monoclonal anti-α-SMA Ab (Sigma;
clone 1A4); anti-Elastin polyclonal Ab (PR387, EPC), anti-FN rabbit polyclonal
Ab (De Langhe et al., 2005) and anti-phospho-p44/42 MAPK (Cell Signaling;
20G11).
RT-PCR
Real-time quantitative RT-PCR analysis was performed on lightcycler
system (Roche) by using the universal probe library. The reactions were
assembled following manufacturer's recommendation with the lightcycler
taqman master kit. The relative cDNA ratio was calculated with Lightcycler
software 4. Beta-actin was used as reference control to normalize equal loading
of template cDNA.
Proliferation and P-ERK assays
Anti-phosho-histone-H3 Ab (Cell signaling) and Anti-P-ERK Ab (cell
signaling) were used to detect proliferation and P-ERK. Labeled epithelial cells
as well as total cell number per section were counted. Three random fields were
chosen (500–800 cells per field). The percent of labeled cells is reported. One-
tailed paired t-test was used for statistical analysis.
Western blotting
Levels of ERK phosphorylation in primary culture of mesenchymal cells
treated with FGFs (R&D) were detected byWestern blot as previously described
(Mailleux et al., 2005).
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